XNK Therapeutics raises SEK 132 million to accelerate growth
Summary
The companys lead investigational candidate drug is currently being evaluated in combination with Sanofis anti-CD38 antibody Sarclisa (Isatuximab) in a Phase II clinical study in multiple myeloma. "XNK Therapeutics and the innovation ecosystem around Karolinska University Hospital in Stockholm have long been at the forefront of clinical cell therapy development" said Ted Fjällman. For more information, please contact: XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The companys platform technology and lead investigational candidate drug was developed specifically to target cancers, including settings where allogeneic cell products are not readily applicable. The Companys objective is for its investigational candidate drug and proprietary platform technology to constitute key components in the cancer treatments of tomorrow.